Rhythm Pharmaceuticals Announces Positive Phase 2 Results for Bivamelagon

Rhythm Pharmaceuticals reported positive Phase 2 results for bivamelagon, its candidate treatment for acquired hypothalamic obesity. The company plans to begin a pivotal Phase 3 trial by the end of 2026, with first patient dosing expected in January 2027.